BioSpace News Archive

Intensity Therapeutics, Inc. announced that data from its open-label Phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, is being presented today, in an oral presentation, at the Connective Tissue Oncology Society Virtual Annual Meeting (CTOS).

AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2021.

Aptevo Therapeutics Inc. today reported its financial results and business highlights for the quarter ended September 30, 2021.

Xenetic Biosciences, Inc. today reported its financial results for the third quarter of 2021 and provided a corporate update.

Cellectis S.A. announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin

Innovation Pharmaceuticals today announced the Company is conducting full data analysis of the Phase 2 Brilacidin COVID-19 clinical trial results to support Brilacidin

Paul Ashton, president and CEO of Inflammasome Therapeutics ( https://inflam.com ), a private company developing therapies for prevalent, degenerative diseases, will be one of the featured speakers at the Inflammasome Therapeutics Summit .

Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12 , 2021

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a new, blinded, post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) in biopsy-confirmed patients with non-alcoholic steatohepatitis (NASH).